As the healthcare ecosystem continues to evolve, life science organizations are placing greater emphasis on evidence that is rigorous, relevant, and aligned across the full product lifecycle. Health Economics and Outcomes Research (HEOR) plays a key role in this shift—informing decisions that span clinical development, market access, and real‑world performance.
A recent HealthEconomics.com podcast brings this topic into focus through a conversation featuring Aaron Berger, Senior Vice President of Evidence Development at UBC, and Dr. Mir Sohail Fazeli, physician‑scientist and founder of Evidinno Outcomes Research—now part of the UBC family. They explore how HEOR is becoming more integrated within modern CRO frameworks and how this evolution drives better evidence delivery for sponsors and stakeholders.
HEOR as a Strategic Partner in Modern CROs
In the discussion, Dr. Fazeli describes how HEOR has matured into a discipline that informs decisions well beyond traditional cost‑effectiveness evaluations. Today, HEOR research shapes upstream development strategies by helping sponsors understand which outcomes matter most, how value may be interpreted by global stakeholders, and where real‑world evidence can complement clinical findings.
Aaron Berger highlights how this strategic integration strengthens CRO partnerships—aligning clinical, observational, and economic evidence strategies to better address the needs of regulators, HTA bodies, payers, providers, and patients.
As Evidinno joins UBC, this unified approach strengthens the ability to deliver comprehensive evidence solutions that anticipate evolving stakeholder needs.
Learn More
To explore the full discussion and hear directly from Aaron Berger and Dr. Mir Sohail Fazeli, check out the full episode: https://healtheconomics.com/integrated-evidence-delivery-the-strategic-role-of-heor-in-modern-cros/
